RNS Number : 3736W
Alliance Pharma PLC
23 April 2021



                                         23 April 2021




("Alliance" or the "Group")


2021 Annual General Meeting (AGM)


Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Notice of AGM 2021 is now available on the Group's website,


Printed copies of the Notice of AGM have been posted to those shareholders who have opted out of receiving electronic communications from the Group.


The AGM will be held at 10.00am on 19 May 2021 at Alliance's head office, Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB


Important notice re COVID-19 and the 2021 AGM


Due to the ongoing uncertainty relating to COVID-19 and the Government's current guidance, it is intended that the 2021 AGM will be held as a hybrid meeting with an appropriate quorum to transact the business of the meeting alongside a live and interactive broadcast to shareholders.


The health and safety of our shareholders and colleagues remains a priority and as such we strongly urge that all shareholders do not attend the AGM in person this year. Further details of how shareholders can fully take part in the AGM remotely are included in the Notice of AGM.


The Board strongly recommends that shareholders register their votes in advance of the meeting by appointing the Chairman of the AGM as proxy, with their voting instructions. Further details are included in the Notice of AGM.



For further information:


Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer


Andrew Franklin, Chief Financial Officer



+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele


Corporate Broking: James Black



Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams


Corporate Broking: Patrick Robb



About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.